The phase 1 trial aimed to evaluate the safety and efficacy of escalating AZD1390 doses with RT in brain malignancies. AZD1390 with IMRT showed manageable safety and potential as a GBM radiosensitizer; clinical trials continue. Glioblastoma multiforme (GBM), the most common primary brain cancer in adults, is an aggressive malignancy with limited life […]...
AACR 2024
Coverage of American Association of Cancer Research Annual Meeting 2024
Apr 05
-Apr 10, 2024